{"disease":{"id":"non-muscle-invasive-bladder-urothelial-carcinoma","name":"non muscle invasive bladder urothelial carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06167356","title":"Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT07322263","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Michael A. O'Donnell","has_results":false},{"nct_id":"NCT06020807","title":"Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Nucleix Ltd.","has_results":false},{"nct_id":"NCT04164082","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":161,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06770582","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07302230","title":"Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05946369","title":"Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT06396533","title":"Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)","phase":"","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT06503614","title":"A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"John Sfakianos","has_results":false},{"nct_id":"NCT05375903","title":"A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"UroGen Pharma Ltd.","has_results":false},{"nct_id":"NCT07064863","title":"A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":31,"lead_sponsor_name":"Queen's University","has_results":false},{"nct_id":"NCT03914794","title":"A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT06766266","title":"Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT06443944","title":"An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"CG Oncology, Inc.","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}